nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—CYP3A4—bone cancer	0.641	1	CbGaD
Bosentan—ABCB11—Doxorubicin—bone cancer	0.105	0.732	CbGbCtD
Bosentan—CYP2C9—Cisplatin—bone cancer	0.0276	0.193	CbGbCtD
Bosentan—CYP3A4—Doxorubicin—bone cancer	0.0107	0.0752	CbGbCtD
Bosentan—ABCB11—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00311	0.0729	CbGpPWpGaD
Bosentan—ABCB11—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00182	0.0426	CbGpPWpGaD
Bosentan—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00179	0.0418	CbGpPWpGaD
Bosentan—ABCB11—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.00166	0.0389	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—GNA11—bone cancer	0.00152	0.0357	CbGpPWpGaD
Bosentan—EDNRA—EGFR-dependent Endothelin signaling events—EGFR—bone cancer	0.00147	0.0345	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Other—GRM1—bone cancer	0.00126	0.0295	CbGpPWpGaD
Bosentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.00111	0.026	CbGpPWpGaD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0011	0.0259	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—GNA11—bone cancer	0.00109	0.0255	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00106	0.0247	CbGpPWpGaD
Bosentan—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00104	0.0244	CbGpPWpGaD
Bosentan—EDNRB—G alpha (q) signalling events—GRM1—bone cancer	0.00099	0.0232	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Other—SMO—bone cancer	0.000889	0.0208	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000886	0.0207	CbGpPWpGaD
Bosentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000793	0.0186	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000728	0.0171	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—GRM1—bone cancer	0.000709	0.0166	CbGpPWpGaD
Bosentan—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000685	0.016	CbGpPWpGaD
Bosentan—EDNRB—G alpha (q) signalling events—GNA11—bone cancer	0.000638	0.0149	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000634	0.0148	CbGpPWpGaD
Bosentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000596	0.014	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—GRM4—bone cancer	0.000576	0.0135	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000571	0.0134	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—JUN—bone cancer	0.000552	0.0129	CbGpPWpGaD
Bosentan—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000533	0.0125	CbGpPWpGaD
Bosentan—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000512	0.012	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—GRM1—bone cancer	0.0005	0.0117	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000475	0.0111	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—GNA11—bone cancer	0.000457	0.0107	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—GRM4—bone cancer	0.000412	0.00966	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000409	0.00957	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—JUN—bone cancer	0.000395	0.00925	CbGpPWpGaD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000393	0.00921	CbGpPWpGaD
Bosentan—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000366	0.00857	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—GRM1—bone cancer	0.000358	0.00837	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—SMO—bone cancer	0.000352	0.00824	CbGpPWpGaD
Bosentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000348	0.00816	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—GRM4—bone cancer	0.000326	0.00763	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—RGS1—bone cancer	0.000326	0.00763	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000313	0.00734	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—GRM4—bone cancer	0.000296	0.00692	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—RGS1—bone cancer	0.000296	0.00692	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—GRM1—bone cancer	0.000282	0.00661	CbGpPWpGaD
Bosentan—Hyperglycaemia—Epirubicin—bone cancer	0.000275	0.00159	CcSEcCtD
Bosentan—Angina pectoris—Doxorubicin—bone cancer	0.000275	0.00159	CcSEcCtD
Bosentan—Hepatobiliary disease—Methotrexate—bone cancer	0.000275	0.00159	CcSEcCtD
Bosentan—Epistaxis—Methotrexate—bone cancer	0.000274	0.00158	CcSEcCtD
Bosentan—Pneumonia—Epirubicin—bone cancer	0.000273	0.00158	CcSEcCtD
Bosentan—Infestation—Epirubicin—bone cancer	0.000272	0.00157	CcSEcCtD
Bosentan—Infestation NOS—Epirubicin—bone cancer	0.000272	0.00157	CcSEcCtD
Bosentan—Bronchitis—Doxorubicin—bone cancer	0.000271	0.00157	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000269	0.00156	CcSEcCtD
Bosentan—Renal failure—Epirubicin—bone cancer	0.000267	0.00154	CcSEcCtD
Bosentan—Body temperature increased—Cisplatin—bone cancer	0.000267	0.00154	CcSEcCtD
Bosentan—Stomatitis—Epirubicin—bone cancer	0.000265	0.00153	CcSEcCtD
Bosentan—Jaundice—Epirubicin—bone cancer	0.000265	0.00153	CcSEcCtD
Bosentan—Urinary tract infection—Epirubicin—bone cancer	0.000264	0.00153	CcSEcCtD
Bosentan—Conjunctivitis—Epirubicin—bone cancer	0.000264	0.00153	CcSEcCtD
Bosentan—Dysuria—Doxorubicin—bone cancer	0.000264	0.00152	CcSEcCtD
Bosentan—Neutropenia—Doxorubicin—bone cancer	0.000264	0.00152	CcSEcCtD
Bosentan—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000262	0.00152	CcSEcCtD
Bosentan—Haemoglobin—Methotrexate—bone cancer	0.000262	0.00151	CcSEcCtD
Bosentan—Hepatitis—Methotrexate—bone cancer	0.000261	0.00151	CcSEcCtD
Bosentan—Haemorrhage—Methotrexate—bone cancer	0.000261	0.00151	CcSEcCtD
Bosentan—Pollakiuria—Doxorubicin—bone cancer	0.000261	0.00151	CcSEcCtD
Bosentan—Haematuria—Epirubicin—bone cancer	0.000259	0.0015	CcSEcCtD
Bosentan—Urinary tract disorder—Methotrexate—bone cancer	0.000258	0.00149	CcSEcCtD
Bosentan—Hepatobiliary disease—Epirubicin—bone cancer	0.000257	0.00149	CcSEcCtD
Bosentan—Weight increased—Doxorubicin—bone cancer	0.000257	0.00148	CcSEcCtD
Bosentan—Epistaxis—Epirubicin—bone cancer	0.000256	0.00148	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—GRM1—bone cancer	0.000256	0.006	CbGpPWpGaD
Bosentan—Urethral disorder—Methotrexate—bone cancer	0.000256	0.00148	CcSEcCtD
Bosentan—Weight decreased—Doxorubicin—bone cancer	0.000255	0.00147	CcSEcCtD
Bosentan—Sinusitis—Epirubicin—bone cancer	0.000255	0.00147	CcSEcCtD
Bosentan—Hyperglycaemia—Doxorubicin—bone cancer	0.000254	0.00147	CcSEcCtD
Bosentan—Pneumonia—Doxorubicin—bone cancer	0.000253	0.00146	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—SMO—bone cancer	0.000252	0.0059	CbGpPWpGaD
Bosentan—Infestation NOS—Doxorubicin—bone cancer	0.000252	0.00145	CcSEcCtD
Bosentan—Infestation—Doxorubicin—bone cancer	0.000252	0.00145	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000249	0.00144	CcSEcCtD
Bosentan—Hypersensitivity—Cisplatin—bone cancer	0.000249	0.00144	CcSEcCtD
Bosentan—Bradycardia—Epirubicin—bone cancer	0.000248	0.00144	CcSEcCtD
Bosentan—Renal failure—Doxorubicin—bone cancer	0.000247	0.00143	CcSEcCtD
Bosentan—Erythema multiforme—Methotrexate—bone cancer	0.000247	0.00142	CcSEcCtD
Bosentan—Haemoglobin—Epirubicin—bone cancer	0.000245	0.00142	CcSEcCtD
Bosentan—Stomatitis—Doxorubicin—bone cancer	0.000245	0.00142	CcSEcCtD
Bosentan—Jaundice—Doxorubicin—bone cancer	0.000245	0.00142	CcSEcCtD
Bosentan—Urinary tract infection—Doxorubicin—bone cancer	0.000244	0.00141	CcSEcCtD
Bosentan—Conjunctivitis—Doxorubicin—bone cancer	0.000244	0.00141	CcSEcCtD
Bosentan—Hepatitis—Epirubicin—bone cancer	0.000244	0.00141	CcSEcCtD
Bosentan—Haemorrhage—Epirubicin—bone cancer	0.000244	0.00141	CcSEcCtD
Bosentan—Eye disorder—Methotrexate—bone cancer	0.000244	0.00141	CcSEcCtD
Bosentan—Tinnitus—Methotrexate—bone cancer	0.000243	0.00141	CcSEcCtD
Bosentan—Hypoaesthesia—Epirubicin—bone cancer	0.000243	0.0014	CcSEcCtD
Bosentan—Asthenia—Cisplatin—bone cancer	0.000242	0.0014	CcSEcCtD
Bosentan—Cardiac disorder—Methotrexate—bone cancer	0.000242	0.0014	CcSEcCtD
Bosentan—Urinary tract disorder—Epirubicin—bone cancer	0.000241	0.00139	CcSEcCtD
Bosentan—Oedema peripheral—Epirubicin—bone cancer	0.00024	0.00139	CcSEcCtD
Bosentan—Haematuria—Doxorubicin—bone cancer	0.00024	0.00139	CcSEcCtD
Bosentan—Urethral disorder—Epirubicin—bone cancer	0.000239	0.00138	CcSEcCtD
Bosentan—Hepatobiliary disease—Doxorubicin—bone cancer	0.000238	0.00137	CcSEcCtD
Bosentan—Epistaxis—Doxorubicin—bone cancer	0.000237	0.00137	CcSEcCtD
Bosentan—Angiopathy—Methotrexate—bone cancer	0.000237	0.00137	CcSEcCtD
Bosentan—Sinusitis—Doxorubicin—bone cancer	0.000236	0.00136	CcSEcCtD
Bosentan—Immune system disorder—Methotrexate—bone cancer	0.000236	0.00136	CcSEcCtD
Bosentan—Mediastinal disorder—Methotrexate—bone cancer	0.000235	0.00136	CcSEcCtD
Bosentan—Chills—Methotrexate—bone cancer	0.000234	0.00135	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—RGS1—bone cancer	0.000233	0.00546	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—GRM4—bone cancer	0.000233	0.00546	CbGpPWpGaD
Bosentan—Diarrhoea—Cisplatin—bone cancer	0.000231	0.00133	CcSEcCtD
Bosentan—Erythema multiforme—Epirubicin—bone cancer	0.000231	0.00133	CcSEcCtD
Bosentan—Bradycardia—Doxorubicin—bone cancer	0.00023	0.00133	CcSEcCtD
Bosentan—Mental disorder—Methotrexate—bone cancer	0.000228	0.00132	CcSEcCtD
Bosentan—Eye disorder—Epirubicin—bone cancer	0.000228	0.00132	CcSEcCtD
Bosentan—Tinnitus—Epirubicin—bone cancer	0.000228	0.00131	CcSEcCtD
Bosentan—Malnutrition—Methotrexate—bone cancer	0.000227	0.00131	CcSEcCtD
Bosentan—Erythema—Methotrexate—bone cancer	0.000227	0.00131	CcSEcCtD
Bosentan—Haemoglobin—Doxorubicin—bone cancer	0.000227	0.00131	CcSEcCtD
Bosentan—Flushing—Epirubicin—bone cancer	0.000226	0.00131	CcSEcCtD
Bosentan—Cardiac disorder—Epirubicin—bone cancer	0.000226	0.00131	CcSEcCtD
Bosentan—Haemorrhage—Doxorubicin—bone cancer	0.000226	0.0013	CcSEcCtD
Bosentan—Hepatitis—Doxorubicin—bone cancer	0.000226	0.0013	CcSEcCtD
Bosentan—Hypoaesthesia—Doxorubicin—bone cancer	0.000225	0.0013	CcSEcCtD
Bosentan—Urinary tract disorder—Doxorubicin—bone cancer	0.000223	0.00129	CcSEcCtD
Bosentan—Oedema peripheral—Doxorubicin—bone cancer	0.000222	0.00129	CcSEcCtD
Bosentan—Angiopathy—Epirubicin—bone cancer	0.000221	0.00128	CcSEcCtD
Bosentan—Urethral disorder—Doxorubicin—bone cancer	0.000221	0.00128	CcSEcCtD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000221	0.00518	CbGpPWpGaD
Bosentan—Immune system disorder—Epirubicin—bone cancer	0.00022	0.00127	CcSEcCtD
Bosentan—Mediastinal disorder—Epirubicin—bone cancer	0.00022	0.00127	CcSEcCtD
Bosentan—Back pain—Methotrexate—bone cancer	0.00022	0.00127	CcSEcCtD
Bosentan—Chills—Epirubicin—bone cancer	0.000219	0.00127	CcSEcCtD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000218	0.00511	CbGpPWpGaD
Bosentan—Vomiting—Cisplatin—bone cancer	0.000215	0.00124	CcSEcCtD
Bosentan—Vision blurred—Methotrexate—bone cancer	0.000214	0.00124	CcSEcCtD
Bosentan—Mental disorder—Epirubicin—bone cancer	0.000214	0.00124	CcSEcCtD
Bosentan—Erythema multiforme—Doxorubicin—bone cancer	0.000213	0.00123	CcSEcCtD
Bosentan—Rash—Cisplatin—bone cancer	0.000213	0.00123	CcSEcCtD
Bosentan—Dermatitis—Cisplatin—bone cancer	0.000213	0.00123	CcSEcCtD
Bosentan—Erythema—Epirubicin—bone cancer	0.000212	0.00123	CcSEcCtD
Bosentan—Malnutrition—Epirubicin—bone cancer	0.000212	0.00123	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—RGS1—bone cancer	0.000212	0.00496	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—GRM4—bone cancer	0.000212	0.00496	CbGpPWpGaD
Bosentan—Eye disorder—Doxorubicin—bone cancer	0.000211	0.00122	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—bone cancer	0.000211	0.00122	CcSEcCtD
Bosentan—Anaemia—Methotrexate—bone cancer	0.00021	0.00121	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—bone cancer	0.00021	0.00121	CcSEcCtD
Bosentan—Flushing—Doxorubicin—bone cancer	0.00021	0.00121	CcSEcCtD
Bosentan—Flatulence—Epirubicin—bone cancer	0.000209	0.00121	CcSEcCtD
Bosentan—Back pain—Epirubicin—bone cancer	0.000205	0.00119	CcSEcCtD
Bosentan—Angiopathy—Doxorubicin—bone cancer	0.000205	0.00118	CcSEcCtD
Bosentan—Muscle spasms—Epirubicin—bone cancer	0.000204	0.00118	CcSEcCtD
Bosentan—Immune system disorder—Doxorubicin—bone cancer	0.000204	0.00118	CcSEcCtD
Bosentan—Vertigo—Methotrexate—bone cancer	0.000204	0.00118	CcSEcCtD
Bosentan—Mediastinal disorder—Doxorubicin—bone cancer	0.000203	0.00118	CcSEcCtD
Bosentan—Leukopenia—Methotrexate—bone cancer	0.000203	0.00117	CcSEcCtD
Bosentan—Chills—Doxorubicin—bone cancer	0.000203	0.00117	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—GRM1—bone cancer	0.000202	0.00473	CbGpPWpGaD
Bosentan—Nausea—Cisplatin—bone cancer	0.000201	0.00116	CcSEcCtD
Bosentan—Vision blurred—Epirubicin—bone cancer	0.0002	0.00116	CcSEcCtD
Bosentan—Cough—Methotrexate—bone cancer	0.000198	0.00114	CcSEcCtD
Bosentan—Mental disorder—Doxorubicin—bone cancer	0.000198	0.00114	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—bone cancer	0.000197	0.00114	CcSEcCtD
Bosentan—Erythema—Doxorubicin—bone cancer	0.000197	0.00114	CcSEcCtD
Bosentan—Anaemia—Epirubicin—bone cancer	0.000196	0.00113	CcSEcCtD
Bosentan—Flatulence—Doxorubicin—bone cancer	0.000194	0.00112	CcSEcCtD
Bosentan—Chest pain—Methotrexate—bone cancer	0.000193	0.00112	CcSEcCtD
Bosentan—Arthralgia—Methotrexate—bone cancer	0.000193	0.00112	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000192	0.00111	CcSEcCtD
Bosentan—Discomfort—Methotrexate—bone cancer	0.000191	0.0011	CcSEcCtD
Bosentan—Vertigo—Epirubicin—bone cancer	0.000191	0.0011	CcSEcCtD
Bosentan—Syncope—Epirubicin—bone cancer	0.00019	0.0011	CcSEcCtD
Bosentan—Leukopenia—Epirubicin—bone cancer	0.00019	0.0011	CcSEcCtD
Bosentan—Back pain—Doxorubicin—bone cancer	0.00019	0.0011	CcSEcCtD
Bosentan—Muscle spasms—Doxorubicin—bone cancer	0.000189	0.00109	CcSEcCtD
Bosentan—Palpitations—Epirubicin—bone cancer	0.000188	0.00108	CcSEcCtD
Bosentan—Loss of consciousness—Epirubicin—bone cancer	0.000187	0.00108	CcSEcCtD
Bosentan—Cough—Epirubicin—bone cancer	0.000185	0.00107	CcSEcCtD
Bosentan—Anaphylactic shock—Methotrexate—bone cancer	0.000185	0.00107	CcSEcCtD
Bosentan—Vision blurred—Doxorubicin—bone cancer	0.000185	0.00107	CcSEcCtD
Bosentan—Infection—Methotrexate—bone cancer	0.000184	0.00106	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—GRM1—bone cancer	0.000183	0.0043	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—GNA11—bone cancer	0.000182	0.00426	CbGpPWpGaD
Bosentan—Nervous system disorder—Methotrexate—bone cancer	0.000182	0.00105	CcSEcCtD
Bosentan—Anaemia—Doxorubicin—bone cancer	0.000182	0.00105	CcSEcCtD
Bosentan—Thrombocytopenia—Methotrexate—bone cancer	0.000181	0.00105	CcSEcCtD
Bosentan—Chest pain—Epirubicin—bone cancer	0.000181	0.00105	CcSEcCtD
Bosentan—Arthralgia—Epirubicin—bone cancer	0.000181	0.00105	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—SMO—bone cancer	0.000181	0.00423	CbGpPWpGaD
Bosentan—Anxiety—Epirubicin—bone cancer	0.00018	0.00104	CcSEcCtD
Bosentan—Skin disorder—Methotrexate—bone cancer	0.00018	0.00104	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00018	0.00104	CcSEcCtD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000179	0.0042	CbGpPWpGaD
Bosentan—Hyperhidrosis—Methotrexate—bone cancer	0.000179	0.00104	CcSEcCtD
Bosentan—Discomfort—Epirubicin—bone cancer	0.000179	0.00103	CcSEcCtD
Bosentan—Dry mouth—Epirubicin—bone cancer	0.000177	0.00102	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—bone cancer	0.000177	0.00102	CcSEcCtD
Bosentan—Anorexia—Methotrexate—bone cancer	0.000177	0.00102	CcSEcCtD
Bosentan—Syncope—Doxorubicin—bone cancer	0.000176	0.00102	CcSEcCtD
Bosentan—Leukopenia—Doxorubicin—bone cancer	0.000176	0.00102	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GRM4—bone cancer	0.000175	0.00409	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RGS1—bone cancer	0.000175	0.00409	CbGpPWpGaD
Bosentan—Palpitations—Doxorubicin—bone cancer	0.000174	0.001	CcSEcCtD
Bosentan—Anaphylactic shock—Epirubicin—bone cancer	0.000173	0.001	CcSEcCtD
Bosentan—Oedema—Epirubicin—bone cancer	0.000173	0.001	CcSEcCtD
Bosentan—Hypotension—Methotrexate—bone cancer	0.000173	0.001	CcSEcCtD
Bosentan—Loss of consciousness—Doxorubicin—bone cancer	0.000173	0.000998	CcSEcCtD
Bosentan—Infection—Epirubicin—bone cancer	0.000172	0.000995	CcSEcCtD
Bosentan—Cough—Doxorubicin—bone cancer	0.000172	0.000991	CcSEcCtD
Bosentan—ABCB11—Metabolism—NDUFA12—bone cancer	0.000171	0.00401	CbGpPWpGaD
Bosentan—Shock—Epirubicin—bone cancer	0.000171	0.000986	CcSEcCtD
Bosentan—Nervous system disorder—Epirubicin—bone cancer	0.00017	0.000983	CcSEcCtD
Bosentan—Thrombocytopenia—Epirubicin—bone cancer	0.00017	0.000981	CcSEcCtD
Bosentan—Tachycardia—Epirubicin—bone cancer	0.000169	0.000978	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000169	0.000975	CcSEcCtD
Bosentan—Skin disorder—Epirubicin—bone cancer	0.000168	0.000973	CcSEcCtD
Bosentan—Hyperhidrosis—Epirubicin—bone cancer	0.000168	0.000969	CcSEcCtD
Bosentan—Insomnia—Methotrexate—bone cancer	0.000168	0.000968	CcSEcCtD
Bosentan—Arthralgia—Doxorubicin—bone cancer	0.000167	0.000967	CcSEcCtD
Bosentan—Chest pain—Doxorubicin—bone cancer	0.000167	0.000967	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—bone cancer	0.000167	0.000964	CcSEcCtD
Bosentan—Paraesthesia—Methotrexate—bone cancer	0.000166	0.000961	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000166	0.00096	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—bone cancer	0.000165	0.000956	CcSEcCtD
Bosentan—Anorexia—Epirubicin—bone cancer	0.000165	0.000955	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—GNA11—bone cancer	0.000165	0.00387	CbGpPWpGaD
Bosentan—Dyspnoea—Methotrexate—bone cancer	0.000165	0.000955	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—IL3—bone cancer	0.000165	0.00386	CbGpPWpGaD
Bosentan—Somnolence—Methotrexate—bone cancer	0.000165	0.000952	CcSEcCtD
Bosentan—Dry mouth—Doxorubicin—bone cancer	0.000164	0.000946	CcSEcCtD
Bosentan—Dyspepsia—Methotrexate—bone cancer	0.000163	0.000942	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000163	0.00381	CbGpPWpGaD
Bosentan—Hypotension—Epirubicin—bone cancer	0.000162	0.000936	CcSEcCtD
Bosentan—Decreased appetite—Methotrexate—bone cancer	0.000161	0.000931	CcSEcCtD
Bosentan—Anaphylactic shock—Doxorubicin—bone cancer	0.00016	0.000927	CcSEcCtD
Bosentan—Oedema—Doxorubicin—bone cancer	0.00016	0.000927	CcSEcCtD
Bosentan—Gastrointestinal disorder—Methotrexate—bone cancer	0.00016	0.000924	CcSEcCtD
Bosentan—Fatigue—Methotrexate—bone cancer	0.00016	0.000923	CcSEcCtD
Bosentan—Infection—Doxorubicin—bone cancer	0.000159	0.000921	CcSEcCtD
Bosentan—Pain—Methotrexate—bone cancer	0.000158	0.000916	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000158	0.000913	CcSEcCtD
Bosentan—Shock—Doxorubicin—bone cancer	0.000158	0.000912	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—bone cancer	0.000157	0.000909	CcSEcCtD
Bosentan—Thrombocytopenia—Doxorubicin—bone cancer	0.000157	0.000908	CcSEcCtD
Bosentan—Insomnia—Epirubicin—bone cancer	0.000157	0.000906	CcSEcCtD
Bosentan—Tachycardia—Doxorubicin—bone cancer	0.000157	0.000905	CcSEcCtD
Bosentan—Skin disorder—Doxorubicin—bone cancer	0.000156	0.000901	CcSEcCtD
Bosentan—Paraesthesia—Epirubicin—bone cancer	0.000156	0.0009	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—bone cancer	0.000155	0.000896	CcSEcCtD
Bosentan—Dyspnoea—Epirubicin—bone cancer	0.000155	0.000893	CcSEcCtD
Bosentan—Somnolence—Epirubicin—bone cancer	0.000154	0.000891	CcSEcCtD
Bosentan—Anorexia—Doxorubicin—bone cancer	0.000153	0.000884	CcSEcCtD
Bosentan—Dyspepsia—Epirubicin—bone cancer	0.000153	0.000882	CcSEcCtD
Bosentan—Gastrointestinal pain—Methotrexate—bone cancer	0.000151	0.000876	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GRM1—bone cancer	0.000151	0.00355	CbGpPWpGaD
Bosentan—Decreased appetite—Epirubicin—bone cancer	0.000151	0.000871	CcSEcCtD
Bosentan—Hypotension—Doxorubicin—bone cancer	0.00015	0.000866	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—IL3—bone cancer	0.00015	0.00351	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Epirubicin—bone cancer	0.00015	0.000865	CcSEcCtD
Bosentan—Fatigue—Epirubicin—bone cancer	0.000149	0.000864	CcSEcCtD
Bosentan—Pain—Epirubicin—bone cancer	0.000148	0.000857	CcSEcCtD
Bosentan—Constipation—Epirubicin—bone cancer	0.000148	0.000857	CcSEcCtD
Bosentan—Urticaria—Methotrexate—bone cancer	0.000147	0.000851	CcSEcCtD
Bosentan—Body temperature increased—Methotrexate—bone cancer	0.000146	0.000846	CcSEcCtD
Bosentan—Abdominal pain—Methotrexate—bone cancer	0.000146	0.000846	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000146	0.000845	CcSEcCtD
Bosentan—Insomnia—Doxorubicin—bone cancer	0.000145	0.000839	CcSEcCtD
Bosentan—Paraesthesia—Doxorubicin—bone cancer	0.000144	0.000832	CcSEcCtD
Bosentan—Dyspnoea—Doxorubicin—bone cancer	0.000143	0.000827	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—bone cancer	0.000143	0.000824	CcSEcCtD
Bosentan—Gastrointestinal pain—Epirubicin—bone cancer	0.000142	0.000819	CcSEcCtD
Bosentan—ABCB11—Metabolism—NT5C3A—bone cancer	0.000142	0.00332	CbGpPWpGaD
Bosentan—Dyspepsia—Doxorubicin—bone cancer	0.000141	0.000816	CcSEcCtD
Bosentan—Decreased appetite—Doxorubicin—bone cancer	0.000139	0.000806	CcSEcCtD
Bosentan—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000138	0.0008	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—bone cancer	0.000138	0.000799	CcSEcCtD
Bosentan—Urticaria—Epirubicin—bone cancer	0.000138	0.000796	CcSEcCtD
Bosentan—Pain—Doxorubicin—bone cancer	0.000137	0.000793	CcSEcCtD
Bosentan—Constipation—Doxorubicin—bone cancer	0.000137	0.000793	CcSEcCtD
Bosentan—Body temperature increased—Epirubicin—bone cancer	0.000137	0.000792	CcSEcCtD
Bosentan—Abdominal pain—Epirubicin—bone cancer	0.000137	0.000792	CcSEcCtD
Bosentan—Hypersensitivity—Methotrexate—bone cancer	0.000136	0.000789	CcSEcCtD
Bosentan—Asthenia—Methotrexate—bone cancer	0.000133	0.000768	CcSEcCtD
Bosentan—Gastrointestinal pain—Doxorubicin—bone cancer	0.000131	0.000758	CcSEcCtD
Bosentan—Pruritus—Methotrexate—bone cancer	0.000131	0.000757	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—GNA11—bone cancer	0.00013	0.00305	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—SMO—bone cancer	0.000129	0.00303	CbGpPWpGaD
Bosentan—Hypersensitivity—Epirubicin—bone cancer	0.000128	0.000738	CcSEcCtD
Bosentan—Urticaria—Doxorubicin—bone cancer	0.000127	0.000737	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—bone cancer	0.000127	0.000733	CcSEcCtD
Bosentan—Body temperature increased—Doxorubicin—bone cancer	0.000127	0.000733	CcSEcCtD
Bosentan—Diarrhoea—Methotrexate—bone cancer	0.000127	0.000733	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—RGS1—bone cancer	0.000125	0.00293	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GRM4—bone cancer	0.000125	0.00293	CbGpPWpGaD
Bosentan—Asthenia—Epirubicin—bone cancer	0.000124	0.000719	CcSEcCtD
Bosentan—Pruritus—Epirubicin—bone cancer	0.000123	0.000709	CcSEcCtD
Bosentan—Dizziness—Methotrexate—bone cancer	0.000123	0.000708	CcSEcCtD
Bosentan—Diarrhoea—Epirubicin—bone cancer	0.000119	0.000686	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—GNA11—bone cancer	0.000118	0.00277	CbGpPWpGaD
Bosentan—Hypersensitivity—Doxorubicin—bone cancer	0.000118	0.000683	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—IL3—bone cancer	0.000118	0.00276	CbGpPWpGaD
Bosentan—Vomiting—Methotrexate—bone cancer	0.000118	0.000681	CcSEcCtD
Bosentan—Rash—Methotrexate—bone cancer	0.000117	0.000675	CcSEcCtD
Bosentan—Dermatitis—Methotrexate—bone cancer	0.000117	0.000674	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000116	0.00272	CbGpPWpGaD
Bosentan—Headache—Methotrexate—bone cancer	0.000116	0.000671	CcSEcCtD
Bosentan—Asthenia—Doxorubicin—bone cancer	0.000115	0.000665	CcSEcCtD
Bosentan—Dizziness—Epirubicin—bone cancer	0.000115	0.000663	CcSEcCtD
Bosentan—Pruritus—Doxorubicin—bone cancer	0.000113	0.000656	CcSEcCtD
Bosentan—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000113	0.00266	CbGpPWpGaD
Bosentan—Vomiting—Epirubicin—bone cancer	0.00011	0.000637	CcSEcCtD
Bosentan—Nausea—Methotrexate—bone cancer	0.00011	0.000636	CcSEcCtD
Bosentan—Diarrhoea—Doxorubicin—bone cancer	0.00011	0.000634	CcSEcCtD
Bosentan—Rash—Epirubicin—bone cancer	0.000109	0.000632	CcSEcCtD
Bosentan—Dermatitis—Epirubicin—bone cancer	0.000109	0.000631	CcSEcCtD
Bosentan—Headache—Epirubicin—bone cancer	0.000109	0.000628	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—GRM1—bone cancer	0.000108	0.00254	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL3—bone cancer	0.000107	0.00251	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SMO—bone cancer	0.000107	0.0025	CbGpPWpGaD
Bosentan—Dizziness—Doxorubicin—bone cancer	0.000106	0.000613	CcSEcCtD
Bosentan—Nausea—Epirubicin—bone cancer	0.000103	0.000595	CcSEcCtD
Bosentan—Vomiting—Doxorubicin—bone cancer	0.000102	0.000589	CcSEcCtD
Bosentan—Rash—Doxorubicin—bone cancer	0.000101	0.000585	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—bone cancer	0.000101	0.000584	CcSEcCtD
Bosentan—Headache—Doxorubicin—bone cancer	0.0001	0.000581	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GNA11—bone cancer	9.76e-05	0.00229	CbGpPWpGaD
Bosentan—Nausea—Doxorubicin—bone cancer	9.53e-05	0.000551	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—CYP3A4—bone cancer	9.53e-05	0.00223	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	9.4e-05	0.0022	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ATF1—bone cancer	9.07e-05	0.00212	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL3—bone cancer	8.85e-05	0.00207	CbGpPWpGaD
Bosentan—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.29e-05	0.00194	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—GSTP1—bone cancer	8.15e-05	0.00191	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	8.04e-05	0.00188	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SMO—bone cancer	7.64e-05	0.00179	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TGFBR2—bone cancer	7.57e-05	0.00177	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IGF1R—bone cancer	7.12e-05	0.00167	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GNA11—bone cancer	6.98e-05	0.00164	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ATF1—bone cancer	6.49e-05	0.00152	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL3—bone cancer	6.33e-05	0.00148	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ENO2—bone cancer	6.21e-05	0.00145	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—DHFR—bone cancer	5.76e-05	0.00135	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NDUFA12—bone cancer	5.71e-05	0.00134	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TGFBR2—bone cancer	5.42e-05	0.00127	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GNA11—bone cancer	5.38e-05	0.00126	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.37e-05	0.00126	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.3e-05	0.00124	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KIT—bone cancer	5.16e-05	0.00121	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IGF1R—bone cancer	5.09e-05	0.00119	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP3A4—bone cancer	4.88e-05	0.00114	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.85e-05	0.00114	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—BRAF—bone cancer	4.85e-05	0.00114	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NT5C3A—bone cancer	4.73e-05	0.00111	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—EGFR—bone cancer	4.7e-05	0.0011	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTP1—bone cancer	4.17e-05	0.000977	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MDM2—bone cancer	4.07e-05	0.000952	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NDUFA12—bone cancer	3.77e-05	0.000882	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KIT—bone cancer	3.7e-05	0.000865	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—JUN—bone cancer	3.53e-05	0.000828	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—BRAF—bone cancer	3.47e-05	0.000813	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MMP9—bone cancer	3.44e-05	0.000805	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—EGFR—bone cancer	3.37e-05	0.000788	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NT5C3A—bone cancer	3.12e-05	0.000731	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MDM2—bone cancer	2.91e-05	0.000682	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EGFR—bone cancer	2.78e-05	0.000651	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—JUN—bone cancer	2.53e-05	0.000592	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MMP9—bone cancer	2.46e-05	0.000576	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—bone cancer	2.33e-05	0.000546	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS2—bone cancer	2.16e-05	0.000506	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ENO2—bone cancer	2.07e-05	0.000485	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EGFR—bone cancer	1.99e-05	0.000466	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—DHFR—bone cancer	1.92e-05	0.00045	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GNA11—bone cancer	1.8e-05	0.000421	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—bone cancer	1.67e-05	0.000391	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP3A4—bone cancer	1.63e-05	0.000382	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.62e-05	0.00038	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTP1—bone cancer	1.39e-05	0.000326	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ENO2—bone cancer	1.37e-05	0.00032	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—DHFR—bone cancer	1.27e-05	0.000297	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GNA11—bone cancer	1.19e-05	0.000278	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTP1—bone cancer	9.19e-06	0.000215	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS2—bone cancer	7.22e-06	0.000169	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS2—bone cancer	4.76e-06	0.000111	CbGpPWpGaD
